These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 189127)

  • 21. [Therapy of pulmonary tuberculosis with reserve drugs in the light of our personal observations].
    Kochnowski G
    Wiad Lek; 1970 Jan; 23(1):9-13. PubMed ID: 4312765
    [No Abstract]   [Full Text] [Related]  

  • 22. [Autonomous treatment of pulmonary tuberculosis with delayed-action drugs].
    Pannain M; Tarantino AB; Mac Dowell A; Costa JA; Cunha JM; Pantoja W
    Rev Bras Med; 1967 Aug; 24(8):664-8. PubMed ID: 5603007
    [No Abstract]   [Full Text] [Related]  

  • 23. [Principles underlying the use of antituberculosis medication in children (author's transl)].
    Ollivier A; Besson-Leaud M
    Sem Hop; 1979 Oct 8-15; 55(33-34):1529-35. PubMed ID: 229564
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Observations on antituberculous drug-resistance among pulmonary tuberculosis patients at the National Sanatoria in Kyushu district. 3. The secondary anti-tuberculosis agents (kanamycin, cycloserine, ethionamide)].
    Yamaguchi S
    Iryo; 1968 Oct; 22(10):1115-9. PubMed ID: 5715475
    [No Abstract]   [Full Text] [Related]  

  • 25. Treatment of drug-resistant tuberculosis.
    Lester W
    Dis Mon; 1971 Apr; ():1-43. PubMed ID: 4327834
    [No Abstract]   [Full Text] [Related]  

  • 26. Bacteriology of tuberculosis with special reference to kanamycin and related drugs.
    Dye WE
    Ann N Y Acad Sci; 1966 Jun; 132(2):901-4. PubMed ID: 4290030
    [No Abstract]   [Full Text] [Related]  

  • 27. [Treatment of drug resistant chronic pulmonary tuberculosis with a number of tuberculostatics].
    Bernard E
    Bull Int Union Tuberc; 1968 Dec; 41():183-7. PubMed ID: 4303862
    [No Abstract]   [Full Text] [Related]  

  • 28. [Treatment with new antitubercular agents].
    Gartmann J
    Dtsch Med Wochenschr; 1968 Nov; 93(47):2281-2. PubMed ID: 4301079
    [No Abstract]   [Full Text] [Related]  

  • 29. [Experimental therapy with so-called "minor" tuberculostatics].
    Freerksen E
    Wien Med Wochenschr; 1966 Oct; 116(42):874-7. PubMed ID: 6005730
    [No Abstract]   [Full Text] [Related]  

  • 30. [Methods of therapy of patients with chronic destructive pulmonary tuberculosis].
    Utkin VV; Rudoĭ NM
    Klin Med (Mosk); 1968 Dec; 46(12):36-43. PubMed ID: 5737381
    [No Abstract]   [Full Text] [Related]  

  • 31. [Resistance of tubercle bacilli to cycloserine, viomycin and ethionamide in patients suffering from pulmonary tuberculosis].
    Srednicka-Zajac D; Mysakowska H; Szarewicz-Adamczyk W; Litwin B
    Ann Univ Mariae Curie Sklodowska Med; 1967; 22():71-8. PubMed ID: 4308440
    [No Abstract]   [Full Text] [Related]  

  • 32. [Therapeutic effects of secondary antitubercular agents at our hospital].
    Nakayama K; Hayashida M; Ishihara M; Ijichi F; Obata Y
    Iryo; 1966 Mar; 20(3):257-63. PubMed ID: 5964832
    [No Abstract]   [Full Text] [Related]  

  • 33. Efficacy and safety of kanamycin, ethionamide, PAS and cycloserine in multidrug-resistant pulmonary tuberculosis patients.
    Prasad R; Verma SK; Sahai S; Kumar S; Jain A
    Indian J Chest Dis Allied Sci; 2006; 48(3):183-6. PubMed ID: 18610675
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Observations on antituberculous drug resistance among pulmonary tuberculosis patients at the national sanatoria in Kyushu district. 4. The primary and the secondary antituberculous agents].
    Yamaguchi S
    Iryo; 1968 Oct; 22(10):1120-4. PubMed ID: 5710123
    [No Abstract]   [Full Text] [Related]  

  • 35. [Clinical problems of resistance to secondary antitubercular agents].
    Baba H; Takahashi R; Nakai T; Torii R; Yo I
    Iryo; 1966 Mar; 20(3):230-40. PubMed ID: 5964830
    [No Abstract]   [Full Text] [Related]  

  • 36. [Secondary antitubercular drugs in the treatment of childhood tuberculosis].
    de Lacerda A
    Rev Port Pediatr Pueric; 1967 May; 30(5):149-56. PubMed ID: 4303078
    [No Abstract]   [Full Text] [Related]  

  • 37. A comparison of ethionamide-cycloserine and ethionamide-pyrazinamide regimens in patients resistant to major chemotherapeutics.
    Vidinel I
    Scand J Respir Dis Suppl; 1970; 71():192-5. PubMed ID: 5271985
    [No Abstract]   [Full Text] [Related]  

  • 38. [Evaluation of the therapeutic effects of secondary antitubercular agents].
    Watanabe S; Nosaki M; Iwasaki M; Hamano S; Furuya Y
    Iryo; 1966 Mar; 20(3):251-6. PubMed ID: 5965119
    [No Abstract]   [Full Text] [Related]  

  • 39. [Bacteriostatic activity of preparations of the 2d series and criteria of the resistance to them].
    Mkrtchian SV; Afanas'eva IuP
    Probl Tuberk; 1967; 45(8):70-5. PubMed ID: 4303640
    [No Abstract]   [Full Text] [Related]  

  • 40. [Effect of cycloserine, ethionamide, and ethoxyd on liver function in pulmonary tuberculosis].
    Baĭl'dinova IM
    Ter Arkh; 1971 Jan; 43(1):101-4. PubMed ID: 5574526
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.